Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal patch for ulixacaltamide in essential tremor.

The latest collaboration news arrives after a period of mixed momentum for Praxis Precision Medicines, with the share price up 11.37% over 30 days but down 8.22% over 90 days, while the 1 year total shareholder return is very large and the 3 year total shareholder return is more than 18x, which may indicate strong longer term sentiment.

If you are interested in other CNS and biotech stories harnessing new delivery or AI tools in healthcare, it could be worth scanning 39 healthcare AI stocks.

Praxis Precision Medicines now sits at the crossroads of a rich CNS pipeline, new delivery technology plans and a share price that has already delivered very large 1 year gains. How is that package actually being valued today?

Most Popular Narrative: 49.1% Undervalued

On the most followed narrative, Praxis Precision Medicines is priced well below its fair value estimate of $617.67 versus the last close at $314.41. This hinges on a set of ambitious earnings and margin assumptions over the coming years.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Want to understand why this fair value sits so far above today’s price? The narrative leans on rapid revenue build, rising margins and a premium future earnings multiple, all tied to a small group of CNS assets reaching scale. The exact mix of growth rates, profitability and share count behind that view might surprise you.

Result: Fair Value of $617.67 (UNDERVALUED)

However, this Praxis Precision Medicines narrative could be quickly tested if key epilepsy trials underperform or if vormatrigine development faces further delays and study changes.

Next Steps

With mixed signals around Praxis Precision Medicines so far, it makes sense to review the full picture quickly and build your own view using the company’s 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Praxis Precision Medicines?

If Praxis Precision Medicines has sharpened your interest, do not stop here. Use the screeners below to quickly surface fresh ideas that fit different investing styles.

• Spot potential value opportunities early by reviewing companies flagged in the 47 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses highlighted in the 82 resilient stocks with low risk scores.
• Hunt for potential future standouts by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.